| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | President, Head of R&D | Stock Options (Right to buy) | 69.4K | $1.55M | $22.28 | Feb 7, 2024 | Direct |
| Syndax Pharmaceuticals Inc | President, Head of R&D | Common Stock | 47.8K | $873K | $18.27 | Feb 7, 2024 | Direct |
| Zymeworks Inc. | Director | Stock Option (Right to Buy) | 31K | Dec 10, 2024 | Direct | ||
| Zymeworks Inc. | Director | No securities are beneficially owned | 0 | Apr 2, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ZYME | Zymeworks Inc. | Dec 10, 2024 | 1 | $0 | 4 | Dec 12, 2024 | Director |
| ZYME | Zymeworks Inc. | Apr 2, 2024 | 1 | $0 | 4 | Apr 2, 2024 | Director |
| ZYME | Zymeworks Inc. | Apr 2, 2024 | 0 | $0 | 3 | Apr 2, 2024 | Director |
| SNDX | Syndax Pharmaceuticals Inc | Feb 7, 2024 | 3 | $1.55M | 4 | Feb 9, 2024 | President, Head of R&D |
| SNDX | Syndax Pharmaceuticals Inc | Apr 10, 2023 | 1 | $4.84M | 4 | Apr 12, 2023 | President, Head of R&D |
| SNDX | Syndax Pharmaceuticals Inc | Apr 10, 2023 | 0 | $0 | 3 | Apr 12, 2023 | President, Head of R&D |